Vaccination against herpes zoster and postherpetic neuralgia in France: a cost-effectiveness analysis.
about
Herpes zoster epidemiology, management, and disease and economic burden in Europe: a multidisciplinary perspectiveReducing the burden of Herpes Zoster in ItalyCost-effectiveness of vaccination against herpes zoster.ARIZONA study: is the risk of post-herpetic neuralgia and its burden increased in the most elderly patients?Health economic evaluation of vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia in Germany.The humanistic, economic and societal burden of herpes zoster in Europe: a critical reviewSystematic review of models assessing the economic value of routine varicella and herpes zoster vaccination in high-income countries.Cost-effectiveness analysis of a vaccination program for the prevention of herpes zoster and post-herpetic neuralgia in adults aged 50 and over in GermanyHerpes Zoster Immunization in Older Adults Has Big Benefits.Preventing and managing herpes zoster: key actions to foster healthy aging.Herpes zoster vaccine: A health economic evaluation for Switzerland.Shingles (Herpes Zoster) Vaccine (Zostavax(®)): A Review in the Prevention of Herpes Zoster and Postherpetic Neuralgia.COST-EFFECTIVENESS ANALYSIS OF HERPES ZOSTER VACCINATION IN ITALIAN ELDERLY PERSONS.Cost-effectiveness of a herpes zoster vaccination program among the French elderly peopleClinical and economic impact of herpes zoster vaccination in elderly in Italy.Herpes zoster immunization in older adults has big benefits.
P2860
Q26781940-8D22C32C-E22F-4938-8027-8E56278FB0CEQ26998625-A6F13D45-010B-491E-9A87-99796A04678AQ34291150-079FF2BD-5A06-49CB-B552-CA8C93C89726Q34667569-5CB96A08-4A20-4732-9D0A-5F4722968C29Q35000186-B903D6CD-DD7A-4B05-9399-E953CC621745Q35147612-D77A0881-ED7C-4E99-A1A8-43EEA2AE0E3DQ35652212-7DFDC1E7-F1B6-438E-96CE-8EFF506EA897Q35887517-DA06D8AD-E005-4093-AA0E-5B15B14EE4F5Q38384783-024951D1-789E-4258-BF5A-51E5C2FB1743Q38416454-EFF3F593-56CB-456A-A182-93C12AE26420Q38798312-F62475BD-72B6-4842-AF24-27F8F436487AQ38836789-F705E155-C81D-478E-941C-09FAC52F9409Q39394780-D4762E93-E89D-4C2C-BB96-3BA3F43C3B0EQ40591031-DF77A80D-1C1D-4D28-B86A-830174D7DB97Q45937750-6EE4C01F-A6D9-4D2B-9344-78EC4174D066Q49024900-8E124A50-26B0-4245-9236-2E6D3C150F21
P2860
Vaccination against herpes zoster and postherpetic neuralgia in France: a cost-effectiveness analysis.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Vaccination against herpes zos ...... a cost-effectiveness analysis.
@en
Vaccination against herpes zos ...... a cost-effectiveness analysis.
@nl
type
label
Vaccination against herpes zos ...... a cost-effectiveness analysis.
@en
Vaccination against herpes zos ...... a cost-effectiveness analysis.
@nl
prefLabel
Vaccination against herpes zos ...... a cost-effectiveness analysis.
@en
Vaccination against herpes zos ...... a cost-effectiveness analysis.
@nl
P2093
P2860
P356
P1476
Vaccination against herpes zos ...... a cost-effectiveness analysis.
@en
P2093
Aline Gauthier
Emmanuelle Préaud
Gérard Duru
Karine Bloch
Lieven Annemans
Xavier Bresse
P2860
P304
P356
10.1586/ERP.13.19
P577
2013-03-28T00:00:00Z